Morgan Stanley has released a research report stating that the earnings per share forecast for INNOVENT BIO (01801) from 2024 to 2026 has been adjusted from losses of 0.70 yuan, 0.50 yuan, and a profit of 0.14 yuan to losses of 0.78 yuan, 0.47 yuan, and a profit of 0.15 yuan respectively. The Target Price has been slightly raised from 66.5 Hong Kong dollars to 67 Hong Kong dollars, with a rating of 'Shareholding'.

The report mentions that based on the performance of INNOVENT BIO's product revenue in the first half of the year and the third quarter, the year-on-year growth forecast for the core product Tyvyt (sintilimab) has been raised from 15% to 40%. Additionally, the growth forecasts for a series of biological products such as rituximab, adalimumab, and bevacizumab have been increased correspondingly, and it is anticipated that the R&D and sales costs will also rise.